HCM Overzicht aandelen HUTCHMED (China) Limited, samen met haar dochterondernemingen, ontdekt, ontwikkelt en verkoopt doelgerichte therapeutica en immuuntherapieën voor kanker en immunologische ziekten in Hong Kong en internationaal. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
HUTCHMED (China) Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor HUTCHMED (China) Historische aandelenkoersen Huidige aandelenkoers UK£2.33 52 Week Hoogtepunt UK£3.53 52 Week Laag UK£1.90 Bèta 0.76 1 maand verandering 1.53% 3 maanden verandering -26.19% 1 Jaar Verandering 8.39% 3 jaar verandering -44.44% 5 jaar verandering -38.98% Verandering sinds IPO 828.14%
Recent nieuws en updates
Hutchmed Announces NMPA Full Approval for Orpathys (Savolitinib) in China for Patients with Locally Advanced or Metastatic Met Exon 14 NSCLC Jan 14 HUTCHMED (China) Limited Announces NDA Acceptance in China with Priority Review Status for ORPATHYS®? and TAGRISSO®? Combination in Lung Cancer Patients with MET amplication After Progression on First-Line EGFR Inhibitor Therapy Jan 02
Hutchmed (China) Limited Announces Breakthrough Therapy Designation in China for Orpathys®? and Tagrisso®? Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy Dec 12
Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet? Dec 11
New minor risk - Share price stability Dec 09
HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024 Nov 20 Meer updates bekijken
Hutchmed Announces NMPA Full Approval for Orpathys (Savolitinib) in China for Patients with Locally Advanced or Metastatic Met Exon 14 NSCLC Jan 14 HUTCHMED (China) Limited Announces NDA Acceptance in China with Priority Review Status for ORPATHYS®? and TAGRISSO®? Combination in Lung Cancer Patients with MET amplication After Progression on First-Line EGFR Inhibitor Therapy Jan 02
Hutchmed (China) Limited Announces Breakthrough Therapy Designation in China for Orpathys®? and Tagrisso®? Combination in Certain Lung Cancer Patients After Disease Progression on Egfr Inhibitor Therapy Dec 12
Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet? Dec 11
New minor risk - Share price stability Dec 09
HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024 Nov 20
HUTCHMED (China) Limited's (LON:HCM) 27% Jump Shows Its Popularity With Investors Oct 19
HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial Oct 16
Health Check: How Prudently Does HUTCHMED (China) (LON:HCM) Use Debt? Sep 10
Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer Sep 09
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Aug 30
First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023) Aug 05
Analysts Have Made A Financial Statement On HUTCHMED (China) Limited's (LON:HCM) Half-Year Report Aug 02
HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024 Jul 31
Investor sentiment improves as stock rises 16% Jul 17
Consensus EPS estimates upgraded to US$0.11 loss Jul 11
HUTCHMED (China) Limited's (LON:HCM) P/S Still Appears To Be Reasonable Jul 11
HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024 Jun 26
Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology Jun 19
HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China Jun 08
HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine Jun 05
HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology May 25 HUTCHMED (China) Limited Announces Executive Changes
HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China May 15
HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui May 14
HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024 May 09
HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024 Apr 09
HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024 Apr 05
We Think HUTCHMED (China) (LON:HCM) Can Manage Its Debt With Ease Apr 04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status Apr 03
HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC Mar 28
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China Mar 22
HUTCHMED (China) Limited's (LON:HCM) P/S Is Still On The Mark Following 31% Share Price Bounce Mar 14
Investor sentiment improves as stock rises 19% Mar 12
The HUTCHMED (China) Limited (LON:HCM) Analysts Have Been Trimming Their Sales Forecasts Mar 01
HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024 Feb 29
Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022) Feb 29
Consensus revenue estimates decrease by 18% Feb 29
Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session Feb 07
HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024 Feb 01
HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer Jan 30
Consensus EPS estimates increase from loss to US$0.0102 profit Jan 28
New minor risk - Share price stability Jan 23
HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status Jan 11
Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues Dec 18
HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China Dec 13
Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors Dec 01
HUTCHMED (China) (LON:HCM) Is Using Debt Safely Nov 23
Consensus EPS estimates increase from loss to US$0.0051 profit Nov 10
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer Nov 09
Consensus EPS estimates increase from loss to US$0.0016 profit Oct 28
HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan Oct 01
HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer Sep 13
Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Sep 12
Consensus EPS estimates upgraded to US$0.0045 loss Sep 08
New minor risk - Shareholder dilution Aug 31
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer Aug 29
Does HUTCHMED (China) (LON:HCM) Have A Healthy Balance Sheet? Aug 24
HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China Aug 21
Key Executive exercised options to buy UK£6.7m worth of stock. Aug 11
First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022) Aug 02
HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study Jul 22
HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee Jul 14
Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China Jul 12
Consensus estimates of losses per share improve by 42% Jul 12
HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023 Jun 27 HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet Jun 17
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency Jun 16
Consensus EPS estimates upgraded to US$0.25 loss Jun 02 HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review May 31
HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED May 26
HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee May 11
Is HUTCHMED (China) (LON:HCM) A Risky Investment? May 10
With HUTCHMED (China) Limited (LON:HCM) It Looks Like You'll Get What You Pay For Apr 19
Full year 2022 earnings: EPS and revenues exceed analyst expectations Apr 13
Consensus EPS estimates fall by 24%, revenue upgraded Apr 08
CFO & Executive Director recently sold UK£2.4m worth of stock Mar 13
Consensus revenue estimates increase by 12%, EPS downgraded Mar 07
Full year 2022 earnings released: US$0.43 loss per share (vs US$0.25 loss in FY 2021) Mar 01
HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023 Jan 31
HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China Jan 19
Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China Jan 04
HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer Dec 20 Rendement voor aandeelhouders HCM GB Pharmaceuticals GB Markt 7D 1.1% 3.3% 2.5% 1Y 8.4% 0.7% 10.0%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: HCM overtrof de UK Pharmaceuticals industrie, die het afgelopen jaar een rendement 0.7 % opleverde.
Rendement versus markt: HCM presteerde slechter dan UK Market , dat het afgelopen jaar een rendement van 10 % opleverde.
Prijsvolatiliteit Is HCM's price volatile compared to industry and market? HCM volatility HCM Average Weekly Movement 7.5% Pharmaceuticals Industry Average Movement 6.5% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.9% 10% least volatile stocks in GB Market 2.7%
Stabiele aandelenkoers: De aandelenkoers van HCM is de afgelopen 3 maanden volatiel geweest in vergelijking met de UK markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van HCM is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen UK.
Over het bedrijf HUTCHMED (China) Limited, samen met haar dochterondernemingen, ontdekt, ontwikkelt en commercialiseert doelgerichte therapeutica en immuuntherapieën voor kanker en immunologische ziekten in Hong Kong en internationaal. Het bedrijf ontwikkelt Savolitinib voor de behandeling van niet-kleincellige longkanker (NSCLC), papillair niercelcarcinoom (RCC) en maagkanker (GC); en Fruquintinib, een remmer voor colorectale kanker (CRC), borstkanker, maagkanker, microsatellietstabiele-CRC endometriumkanker (EMC), NSCLC, RCC, gastro-intestinale, baarmoederhalskanker en solide tumoren. Het ontwikkelt ook Surufatinib, dat wordt gebruikt voor de behandeling van pancreas neuro-endocriene tumor (NET), niet-pancreatische NET, neuro-endocrien carcinoom, SCLC, galwegkanker en solide tumoren; en Sovleplenib dat hematologische kankers en bepaalde chronische immuunziekten behandelt.
Meer tonen HUTCHMED (China) Limited Samenvatting Hoe verhouden de winst en inkomsten van HUTCHMED (China) zich tot de beurswaarde? HCM fundamentele statistieken Marktkapitalisatie UK£1.94b Inkomsten(TTM ) -UK£34.06m Inkomsten(TTM ) UK£495.71m
4.0x P/S-verhouding
-58.3x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) HCM resultatenrekening (TTM ) Inkomsten US$610.81m Kosten van inkomsten US$658.26m Brutowinst -US$47.45m Overige uitgaven -US$5.48m Inkomsten -US$41.97m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.049 Brutomarge -7.77% Nettowinstmarge -6.87% Schuld/Eigen Vermogen Verhouding 10.9%
Hoe presteerde HCM op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/22 14:31 Aandelenkoers aan het einde van de dag 2025/01/22 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten HUTCHMED (China) Limited wordt gevolgd door 49 analisten. 25 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Jiangqiao Tong BOCI Research Ltd. Linda Lu BOCI Research Ltd. Alec Stranahan BofA Global Research
Toon 46 meer analisten 
